Dr Oheneba Owusu-Danso, the Chief Executive Officer (CEO), said the GH ¢5.4 million contract was approved upon deliberations by the Public Procurement Authority, the National Tender Review Committee and Management of the Hospital.

The acquisition of the plants would save the hospital the current expenditure of GH¢12,000.00 daily on medical oxygen.

Dr. Owusu-Danso who announced this at the 2018 mid-year performance review workshop of KATH said the plants were being procured from the internally generated funds of hospital.

He said preparations were underway for three engineers from the technical services directorate to travel to USA for hands on training in the handling of the equipment prior to its shipment to Ghana.

Dr Owusu-Danso, said the first phase of the Sickle Cell and Blood Centre which was being executed by the Sickle Cell Foundation of Ghana with a $ 4.5 million funding from the Ghana National Petroleum Corporation has begun.

He said management of the facility was taking steps to promote discipline among staff, improve operational efficiencies and attract premium clients.

Management would also work to complete the roll-out of the Hospital’s Biometric Attendance Registration System under which staff members would have to automatically register their presence at work.

The system when fully deployed, will among other things, be used for the validation of staff salaries, promotions, appointments and special recognition.

The Chief Executive said the full automation of the hospital’s operations was expected to be completed by the end of the year.